Glucosylceramidase (GBA) is required for autophagic degradation, and a preclinical study identified GBA as one of the direct targets of ART, which may have promising potential to inhibit lysosomal autophagy for HCC therapy (Chen et al., 2022). Here, GBA1 is linked to hepatocellular carcinoma.